Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 6/20 | 0.58 |
| ▸ | CYP2C9 | P11712 | 4/20 | 0.58 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.58 |
| ▸ | NR1I2 | O75469 | 2/20 | 0.58 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.58 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.58 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.55 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.53 |
| ▸ | PRCP | P42785 | 7/20 | 0.42 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.40 |
| ▸ | OPRD1 | P41143 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16523014 | 0.90 | CYP3A4 (0.48) | CYP3A4CYP2C9KCNH2NR1I2ABCB11 | |
| SCHEMBL16520619 | 0.90 | CYP3A4 (0.48) | CYP3A4CYP2C9KCNH2NR1I2ABCB11 | |
| SCHEMBL16355479 | 0.88 | CYP3A4 (0.65) | CYP3A4CYP2C9KCNH2NR1I2ABCB11 | |
| SCHEMBL16355504 | 0.87 | CYP3A4 (0.63) | CYP3A4CYP2C9KCNH2NR1I2ABCB11 | |
| SCHEMBL16355483 | 0.87 | CYP3A4 (0.63) | CYP3A4CYP2C9KCNH2NR1I2ABCB11 | |
| SCHEMBL16355503 | 0.87 | CYP3A4 (0.63) | CYP3A4CYP2C9KCNH2NR1I2ABCB11 | |
| SCHEMBL16355499 | 0.87 | CYP3A4 (0.63) | CYP3A4CYP2C9KCNH2NR1I2ABCB11 | |
| SCHEMBL16355497 | 0.86 | CYP3A4 (0.58) | CYP3A4CYP2C9KCNH2NR1I2ABCB11 | |
| SCHEMBL16520632 | 0.86 | CYP3A4 (0.55) | CYP3A4CYP2C9KCNH2NR1I2ABCB11 | |
| SCHEMBL16355480 | 0.85 | CYP3A4 (0.61) | CYP3A4CYP2C9KCNH2NR1I2ABCB11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140378416-A1 | SILYL-CONTAINING HETEROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEASES | MERCK SHARP & DOHME CORP. | 2014-12-25 | — | — | US | disclosed |
| US-20140378416-A1 | SILYL-CONTAINING HETEROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEASES | MERCK SHARP & DOHME CORP. | 2014-12-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140378416-A1 | SILYL-CONTAINING HETEROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEASES | ZC3HAV1L, HBS1L, HAVCR2 | CYP3A4 357/4885CYP2C9 378/4885KCNH2 3634/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.